InvestorsObserver
Sign Up Login

AMPE Ampio Pharmaceuticals

$0.31 $0.02 (5.17%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

AMPE Stock Analysis Overview

What this means: Ampio Pharmaceuticals (AMPE) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives AMPE a rank of 23. Our methodology considers analysis of the company's financial situation and how it has traded recently. AMPE rank of 23 means that it ranks below 77% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

AMPE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

AMPE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

AMPE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

AMPE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

AMPE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

AMPE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

AMPE Stock Analysis Overview

What this means: Ampio Pharmaceuticals (AMPE) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives AMPE a rank of 23. Our methodology considers analysis of the company's financial situation and how it has traded recently. AMPE rank of 23 means that it ranks below 77% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full AMPE report

AMPE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

AMPE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

AMPE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

AMPE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

AMPE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

AMPE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Ampio Pharmaceuticals (AMPE) Analyst Forecast

AMPE Price, Volume, Earnings, and Dividend Date

  • Last Price $0.31
  • Previous Close $0.29
  • Change $0.02
  • Open $0.29
  • Volume 122,839
  • Avg. Volume (100-day) 281,513
  • Market Cap 4,379,834
  • Days Range 0.281 - 0.31
  • 52-week Range 0.18 - 3.94
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 11/07/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta -2.701
  • PEG Ratio —

Ampio Pharmaceuticals (AMPE) Company Description

Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and advancement of immunomodulatory therapies for the treatment of pain from osteoarthritis. Its lead product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19 induced respiratory distress.

Ampio Pharmaceuticals (AMPE) Stock Chart

View Interactive AMPE chart

My Watchlists

Top Stocks in Biotechnology